Zhangzhou Pientzehuang Pharmaceutical (600436) Fundamentals 2026 — P/E 44.5x, Revenue Analysis | SniperIQ
Zhangzhou Pientzehuang Pharmaceutical (600436) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥84.5B, trading at ¥140.00 on the SHH. This SniperIQ fundamentals page covers Zhangzhou Pientzehuang Pharmaceutical's valuation (P/E 44.5x, P/B 5.6x), profitability (net margin 22.1%), revenue (¥9.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhangzhou Pientzehuang Pharmaceutical's market cap?
Zhangzhou Pientzehuang Pharmaceutical (600436) has a market capitalization of approximately ¥84.5B, trading at ¥140.00 on the SHH. Market cap moves with the live share price.
What is Zhangzhou Pientzehuang Pharmaceutical's P/E ratio?
Zhangzhou Pientzehuang Pharmaceutical's trailing twelve-month P/E ratio is 44.5x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhangzhou Pientzehuang Pharmaceutical?
Zhangzhou Pientzehuang Pharmaceutical runs a net profit margin of 22.1%, a gross margin of 35.1%, and an operating margin of 22.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhangzhou Pientzehuang Pharmaceutical generate?
Zhangzhou Pientzehuang Pharmaceutical reported revenue of ¥9.0B for fiscal year 2025, with net income of ¥2.2B and earnings per share (EPS) of 3.58. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhangzhou Pientzehuang Pharmaceutical pay a dividend?
Zhangzhou Pientzehuang Pharmaceutical offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhangzhou Pientzehuang Pharmaceutical financially healthy?
Zhangzhou Pientzehuang Pharmaceutical carries a debt-to-equity ratio of 0.07x and a current ratio of 5.02x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhangzhou Pientzehuang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhangzhou Pientzehuang Pharmaceutical (600436) the key facts are: market cap ¥84.5B, P/E 44.5x, revenue ¥9.0B, 52-week range 105.98-218.57. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhangzhou Pientzehuang Pharmaceutical's full fundamentals live
Get Zhangzhou Pientzehuang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.